publication date: Jan. 10, 2020
Issue 2 - Jan. 10, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Guest Editorial

    Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall

    As I look through just-published tables of age-adjusted cancer mortality, I recognize an unprecedented development:

    Immunotherapy is showing such a dramatic impact in the treatment of locally advanced and advanced non-small cell lung cancer that this effect elevates the statistics for all lung cancer and—this I find astonishing—you can even see its effect in age-adjusted cancer mortality overall.

  • Annals corrects NutriRECS red, processed meat papers to reflect industry-related funding from Texas A&M AgriLife

    The Annals of Internal Medicine has published a correction to the controversial meta-analyses of health outcomes related to consumption of red and processed meat—announcing that the lead author of the journal’s “new guidelines,” Bradley Johnston, didn’t disclose funding from AgriLife Research.

  • Top 25 Stories of 2019

    We went through our analytics: here is what your colleagues in oncology read in 2019.

  • NCI advisors approve seven concepts at joint NCAB/BSA meeting

    The NCI Board of Scientific Advisors has approved seven new and reissue concepts—Requests for Applications, Requests for Proposals, and PARs.

  • In Brief

    • Thomas J. Lynch Jr. named president and director of Fred Hutch
    • Aaron Crane named executive VP of Seattle Cancer Care Alliance
    • Bhramar Mukherjee, Christopher Friese named associate directors at Rogel Cancer Center
    • Christopher Ballas appointed SVP at Innovative Cellular Therapeutics
  • Funding Opportunities

    ALK Positive and LUNGevity issue RFA for 2020 ALK-positive Lung Cancer Research Award Program

    ALK Positive/LUNGevity is requesting applications for the 2020 ALK-positive Lung Cancer Research Award. Letters of intent are due Feb. 14.

  • TCCL Logo

  • Trials & Tribulations

    Advancing the science of cancer in Latinos

    Having cancer as a Latino in the United States has important implications potentially related to risk of carcinogenesis, knowledge of cancer prevention, access to cancer screening, therapy timing and choices, and access to good supportive/palliative or survivorship care.

  • Clinical Roundup

    • Keytruda shows mixed results in late-stage lung cancer study
    • Breast density notification laws not effective for all women
    • Researchers surprised by high levels of alcohol consumption among cancer survivors
    • Surgery may add months or years of survival for adults with high-grade gliomas
  • Drugs & Targets

    • FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
    • FDA approves Ayvakit for unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor
    • Enfortumab vedotin gets FDA accelerated approval for advanced urothelial or bladder cancer
    • FDA grants IceCure clearance for expanded indications of cryoablation technology and regulatory approval of MultiSense system
    • Canada approves treatment for relapsed/refractory chronic lymphocytic leukemia as part of Project Orbis collaboration

Copyright (c) 2020 The Cancer Letter Inc.